T-VEC Plus Pembrolizumab Tested in Melanoma After Anti-PD-1 Failure
Phase 2 trial explores whether combining oncolytic virus therapy with immunotherapy can rescue patients whose melanoma progressed on PD-1 blockade.
Summary
Many melanoma patients eventually stop responding to PD-1 checkpoint inhibitors, leaving few good options. This completed phase 2 trial tested whether adding talimogene laherparepvec (T-VEC), an oncolytic herpes virus injected directly into tumors, to pembrolizumab could overcome that resistance. Seventy-two patients with advanced or metastatic melanoma who had already progressed on anti-PD-1 therapy were enrolled across multiple centers. Treatment continued until complete response, all injectable lesions disappeared, disease progression, intolerance, or up to roughly two years. The trial was sponsored by Amgen and ran from early 2020 through early 2024. Results from this study could help define new treatment strategies for a patient population with significant unmet need, potentially offering a path forward when standard immunotherapy has already failed.
Detailed Summary
Melanoma remains one of the most immunotherapy-responsive cancers, yet a substantial proportion of patients eventually progress on PD-1 checkpoint inhibitors like pembrolizumab. For these individuals, treatment options narrow considerably, and identifying effective salvage strategies is a major clinical priority.
This phase 2, open-label, single-arm, multicenter trial — MASTERKEY-115 / KEYNOTE-A07 — evaluated the combination of talimogene laherparepvec (T-VEC) and pembrolizumab in patients with unresectable or metastatic melanoma (stage IIIB through IVM1d) who had progressed on prior anti-PD-1 therapy, either in the metastatic or adjuvant setting. T-VEC is a genetically modified oncolytic herpes simplex virus that selectively replicates in tumor cells and stimulates local and systemic immune responses. The hypothesis was that intratumoral T-VEC could re-sensitize tumors to PD-1 blockade by reshaping the immunosuppressive tumor microenvironment.
Seventy-two patients were enrolled across multiple centers. Treatment was administered until confirmed complete response, disappearance of all injectable lesions, documented disease progression per modified irRC-RECIST criteria, treatment intolerance, or 102 weeks from first dose — whichever came first. The trial was sponsored by Amgen and completed in February 2024.
The combination strategy is biologically compelling: T-VEC drives immunogenic tumor cell death and local cytokine release, potentially converting immunologically 'cold' tumors into 'hot' ones amenable to checkpoint blockade. If the combination demonstrates meaningful response rates in this refractory population, it could offer a much-needed option for patients with limited alternatives.
However, the single-arm design means results must be interpreted without a direct comparator, and the relatively small sample size limits statistical power. Full efficacy and safety data are not yet publicly available from this abstract. Peer-reviewed publication of the complete dataset will be essential to assess the true clinical value of this approach.
Key Findings
- Phase 2 trial tested T-VEC plus pembrolizumab in 72 melanoma patients who failed prior PD-1 therapy.
- T-VEC may re-sensitize PD-1-refractory tumors by converting immunologically cold tumors to hot ones.
- Trial covered both metastatic and adjuvant anti-PD-1 failure settings, broadening applicability.
- Treatment could continue up to 102 weeks, allowing assessment of durable responses.
- Full efficacy and safety results pending peer-reviewed publication from this completed trial.
Methodology
This was a phase 2, open-label, single-arm, multicenter trial enrolling 72 patients with unresectable or metastatic melanoma (stage IIIB–IVM1d) who progressed on prior anti-PD-1 therapy. Response was assessed using modified irRC-RECIST criteria simulating RECIST standards. The trial ran from January 2020 to February 2024 under Amgen sponsorship.
Study Limitations
Summary is based on the abstract only; full efficacy, safety, and response rate data are not yet available in this record. The single-arm design without a control group limits causal inference, and the modest sample size of 72 patients may reduce statistical power. Publication of the complete dataset is necessary before drawing definitive clinical conclusions.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.